References
1. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clinical immunology. 2020:108427.
2. Poyiadji N, Cormier P, Patel PY, et al. Acute pulmonary embolism and COVID-19. Radiology. 2020;297(3):E335-E338.
3. Kerget B, Akgun M, Dogan N. Atypical presentation of COVID-19: Acute renal failure. The Eurasian Journal of Medicine. 2020;52(2):224.
4. Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. 2020.
5. Ichimura T, Mori Y, Aschauer P, et al. KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney. medRxiv. 2020.
6. Yang C, Zhang Y, Chen H, et al. Kidney injury molecule-1 is a potential receptor for SARS-CoV-2. bioRxiv. 2020.
7. Azam TU, Shadid HR, Blakely P, et al. Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI. Journal of the American Society of Nephrology. 2020;31(11):2725-2735.
8. D’Alonzo D, De Fenza M, Pavone V. COVID-19 and pneumonia: a role for the uPA/uPAR system. Drug discovery today. 2020;25(8):1528-1534.
9. Hamie L, Daoud G, Nemer G, et al. SuPAR, an emerging biomarker in kidney and inflammatory diseases. Postgraduate medical journal.2018;94(1115):517-524.
10. Sjoding MW, Hofer TP, Co I, Courey A, Cooke CR, Iwashyna TJ. Interobserver reliability of the Berlin ARDS definition and strategies to improve the reliability of ARDS diagnosis. Chest.2018;153(2):361-367.
11. Peeri NC, Shrestha N, Rahman MS, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? International journal of epidemiology. 2020;49(3):717-726.
12. He R, Lu Z, Zhang L, et al. The clinical course and its correlated immune status in COVID-19 pneumonia. Journal of Clinical Virology. 2020;127:104361.
13. Kerget B, Kerget F, Koçak AO, et al. Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19? Lung. 2020;198(5):777-784.
14. Kerget B, Kerget F, Aksakal A, Aşkın S, Sağlam L, Akgün M. Evaluation of alpha defensin, IL‐1 receptor antagonist, and IL‐18 levels in COVID‐19 patients with macrophage activation syndrome and acute respiratory distress syndrome. Journal of Medical Virology. 2020.
15. Luther T, Bülow‐Anderberg S, Larsson A, et al. COVID‐19 patients in intensive care develop predominantly oliguric acute kidney injury.Acta Anaesthesiologica Scandinavica. 2020.
16. Rabaan AA, Al-Ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med. 2020;28(2):174-184.
17. Wu C-Z, Chang L-C, Lin Y-F, et al. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy. Clinical biochemistry.2015;48(18):1324-1329.
18. Van Oort PM, Bos LD, Póvoa P, et al. Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia. ERJ open research. 2019;5(1).
19. Tsai P-K, Tsao S-M, Yang W-E, Yeh C-B, Wang H-L, Yang S-F. Plasma soluble urokinase-type plasminogen activator receptor level as a predictor of the severity of community-acquired pneumonia.International journal of environmental research and public health. 2019;16(6):1035.
20. Gumus A, Altintas N, Cinarka H, et al. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. International journal of chronic obstructive pulmonary disease. 2015;10:357.
21. Guthoff M, Wagner R, Randrianarisoa E, et al. Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus. Scientific reports. 2017;7(1):1-7.
22. Theilade S, Lyngbaek S, Hansen T, et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. Journal of internal medicine. 2015;277(3):362-371.
23. Eugen‐Olsen J, Ladelund S, Sørensen LT. Plasma su PAR is lowered by smoking cessation: a randomized controlled study. European journal of clinical investigation. 2016;46(4):305-311.
24. Okulu E, Arsan S, Akin IM, et al. Serum levels of soluble urokinase plasminogen activator receptor in infants with late‐onset sepsis.Journal of clinical laboratory analysis. 2015;29(5):347-352.
25. Hoenigl M, Raggam RB, Wagner J, et al. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.Clinical biochemistry. 2013;46(3):225-229.
26. Donadello K, Scolletta S, Covajes C, Vincent J-L. suPAR as a prognostic biomarker in sepsis. BMC medicine. 2012;10(1):1-9.